Incorporation Of Finasteride-Loaded Microspheres Into Personalized Microneedle For Sustained Transdermal Delivery

This review examines the efficacy of various novel treatments for androgenetic alopecia, including oral minoxidil and platelet-rich plasma, suggesting potential benefits but emphasizing the need for further high-quality clinical trials to thoroughly evaluate their effectiveness.

This review summarizes recent research on microneedles for alopecia treatment and hair regrowth, noting their potential to improve drug delivery and patient outcomes, but reports no new clinical results.

This study estimated the starting dose range for a finasteride long-acting injectable formulation in humans, suggesting that 16.80 mg may be the optimal starting dose.

In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.

This review article highlights how hair follicle-targeting drug delivery systems enhance therapeutic outcomes and reduce side effects for treating conditions like androgenetic alopecia and acne vulgaris. The authors discuss current formulations and evaluate their performance in both preclinical and clinical settings.

This review found that topical finasteride has similar efficacy to oral finasteride in treating male and female pattern hair loss, with fewer systemic side effects, mainly causing localized scalp reactions like irritation and erythema.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This review discusses the potential of microneedles to enhance transdermal drug delivery by expanding the range of deliverable drugs, highlighting fabrication methods, material choices, and applications, but notes existing challenges with sustained delivery, cost-effectiveness, and large-scale production.

This study found that a ceria nanozyme-integrated microneedles patch accelerated hair regeneration in an androgenetic alopecia mouse model more effectively than minoxidil, with reduced application frequency and minimal skin damage.

This study describes the development of microneedle array patches for finasteride that released the drug over 7 to 14 days in vitro, suggesting a potential alternative to oral treatments for long-term management of benign prostatic hyperplasia and androgenic alopecia.

This review discusses the role of telomere length dynamics in hair follicle biology and reports no new clinical findings, emphasizing the need for further research in humans.

In this study, microneedles combined with finasteride nanostructured lipid carriers (FIN-NLC-MNs) were found to enhance skin penetration and specifically target hair follicles, promoting hair growth and gene regulation in androgenetic alopecia.

This review discusses the pharmacology and safety of topical finasteride for treating androgenetic alopecia and female pattern hair loss, noting positive results but reporting no new clinical findings.

In this study, researchers developed a new self-administered finasteride delivery system using powder-carrying microneedles that improved hair growth efficacy and addressed safety concerns compared to topical finasteride gel by allowing sustained intradermal release of the drug for three days with a single application.

This study investigated the use of Minoxidil encapsulated in HA-PLGA nanoparticles for alopecia treatment and found that these nanoparticles efficiently delivered the drug to hair follicle cells without significant cytotoxicity, offering a potential transdermal delivery method for various diseases.

This study observed that a wearable electric stimulation device significantly promoted hair regeneration in rats and mice, outperforming conventional pharmacological treatments and enhancing growth factor secretion.

In this study, finasteride treatment for two years did not significantly reverse miniaturized hair follicles in men with male pattern hair loss, challenging the "reversal hypothesis" as 79 out of 113 miniaturized hairs remained unchanged.

This study found that finasteride-loaded microspheres effectively treated androgenic alopecia in a mouse model, showing similar hair growth effects to orally-administered finasteride.

In this review, the authors discuss the pharmacology of dutasteride and compare its efficacy to finasteride for treating androgenetic alopecia, highlighting dutasteride's effectiveness demonstrated in several clinical trials.

This study found that both topical and oral finasteride had similar therapeutic effects in treating male androgenic alopecia, with no significant differences in hair thickness, counts, or bald area size.